Innoviva, Inc. filings document a Nasdaq-listed common-stock issuer with a royalty healthcare portfolio, Innoviva Specialty Therapeutics operations, and strategic healthcare investments. Form 8-K reports furnish operating results and financial condition, including royalty revenue, IST net product sales, product-portfolio developments, fair-value changes in investments, and capital allocation activity.
Proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, and equity incentive plan approvals. The record also identifies the company’s common stock, par value $0.01 per share, traded under INVA on the Nasdaq Global Select Market.
Innoviva, Inc. reported strong first-quarter 2026 results, with total revenue of $97.994 million, up from $88.632 million a year earlier, driven mainly by higher net product sales. Royalty revenue was $55.167 million, slightly below the prior year, while product sales rose to $41.371 million from $30.279 million, helped by XACDURO and the launch of ZEVTERA.
Net income swung to a profit of $186.595 million from a loss of $46.584 million, largely due to favorable fair value movements in equity method and other investments totaling over $191 million. Operating income from the underlying business was $38.154 million, modestly below the prior-year level as selling, general and administrative expenses increased. Cash and cash equivalents grew to $603.085 million, even after repurchasing about $20.4 million of common stock during the quarter.
Innoviva, Inc. reported a profitable first quarter of 2026, with total revenue of $97,994 thousand and net income of $186,595 thousand. Diluted earnings per share were $2.22, compared with a diluted net loss per share of $0.74 a year earlier.
Royalty revenue, net, was $55,167 thousand, while net product sales rose to $41,371 thousand. Management highlighted Innoviva Specialty Therapeutics, noting IST net product sales growth of 37% year over year, including 29% growth in U.S. sales.
Results were boosted by changes in fair values of equity method investments of $157,650 thousand and equity and long-term investments of $33,575 thousand. Cash and cash equivalents increased to $603,085 thousand as of March 31, 2026, supported by positive operating and investing cash flows.
Innoviva, Inc. reported that Chief Executive Officer Pavel Raifeld was conditionally granted equity awards as part of his compensation. He received 126,646 time-vested restricted stock units representing Common Stock and 312,500 non-statutory stock options with a $22.99 exercise price, subject to stockholder approval of the 2026 Equity Incentive Plan at the 2026 annual meeting on May 4, 2026. Twenty-five percent of each award vests on February 20, 2027, with the remaining portions vesting in twelve substantially equal quarterly installments, assuming continued service and certain change-in-control protections. Following the grant, he directly holds 285,936 shares of Common Stock and 312,500 options.
Innoviva, Inc. director Mark DiPaolo received new equity awards consisting of common stock and stock options. He was granted 9,786 shares of common stock as restricted stock units at no purchase price, increasing his direct holdings to 140,492 shares. He also received a non-statutory stock option for 10,000 shares of common stock at an exercise price of $22.99 per share, expiring in 2036.
According to the award terms, 100% of the RSUs and options will vest at the earlier of the next annual stockholder meeting or the one-year anniversary of the grant, subject to his continued service as an Outside Director. Vesting accelerates upon death, disability, or a qualifying change in control under the company’s 2026 Equity Incentive Plan.
Innoviva, Inc. reported that Chief Accounting Officer Marianne Zhen acquired equity awards as compensation. She was conditionally granted 12,766 time-vested restricted stock units and 31,500 non-statutory stock options with an exercise price of $22.99 per share, each for Innoviva common stock.
The awards are subject to stockholder approval of Innoviva's 2026 Equity Incentive Plan at the 2026 annual meeting on May 4, 2026. Twenty-five percent of both the RSUs and options vest on February 20, 2027, with the remainder vesting in twelve equal quarterly installments, subject to continued service and certain change-in-control and involuntary termination provisions. Following the grant, Zhen directly holds 58,643 common shares and 31,500 options.
Innoviva, Inc. director Sarah J. Schlesinger received new equity compensation awards. She was granted 9,786 shares of common stock in the form of restricted stock units and a non-statutory stock option for 10,000 shares at an exercise price of $22.99 per share.
These grants were made following Innoviva’s 2026 annual meeting of stockholders and are compensation awards, not open-market purchases. All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the grant, contingent on her continued service as an Outside Director, with accelerated vesting upon death, disability, or a qualifying change in control under the 2026 Equity Incentive Plan.
After these awards, she directly holds 140,492 shares of common stock and 10,000 options.
Innoviva, Inc. reported that its Chief Financial Officer, Stephen Basso, received equity-based compensation awards. He was granted 37,994 time-vested restricted stock units of common stock and a non-statutory stock option for 93,750 shares at an exercise price of $22.99 per share.
These RSUs and options were conditionally granted under Innoviva's 2026 Equity Incentive Plan, subject to stockholder approval at the 2026 annual meeting on May 4, 2026. Twenty-five percent of each award vests on February 20, 2027, with the remaining portions vesting in twelve equal quarterly installments, assuming continued service.
The vesting schedule includes potential accelerated vesting in certain change in control and involuntary termination scenarios as defined in the 2026 Equity Incentive Plan. Following the RSU grant, Basso directly holds 88,007 shares of Innoviva common stock.
Innoviva, Inc. director Derek A. Small received equity awards tied to his board service. He acquired 9,786 shares of common stock through restricted stock units at no cost and now holds 45,035 shares directly. He was also granted non-statutory stock options for 10,000 shares of common stock at an exercise price of $22.99 per share, expiring in 2036. All RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of grant, with accelerated vesting upon death, disability, or certain change in control events.
Haimovitz Jules reported acquisition or exercise transactions in this Form 4 filing.
Innoviva, Inc. director Jules Haimovitz received equity compensation in the form of restricted stock units and stock options. He was granted 9,786 shares of Common Stock as RSUs and 10,000 non-statutory stock options, each option exercisable at $22.9900 per share.
All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the May 4, 2026 grant, subject to his continuous service as an Outside Director. Vesting accelerates upon death, disability, or a qualifying change in control under Innoviva’s 2026 Equity Incentive Plan. Following the stock award, Haimovitz directly holds 152,692 shares of Common Stock and 10,000 options.
Innoviva, Inc. reported results from its Annual Meeting of Stockholders held on May 4, 2026. Stockholders elected five directors for one-year terms ending at the 2027 annual meeting, including Chief Executive Officer Pavel Raifeld, with each nominee receiving a strong majority of votes cast.
Stockholders approved, on a non-binding advisory basis, Innoviva’s executive compensation and ratified the Audit Committee’s selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved Innoviva’s 2026 Equity Incentive Plan, supporting the company’s ongoing compensation and governance framework.